Multi-center, Israeli, Non-interventional, Cohort Study of the Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adult Patients Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
Latest Information Update: 09 May 2022
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms BIC-STaR
- Sponsors Gilead Sciences
Most Recent Events
- 29 Apr 2022 Status changed from active, no longer recruiting to completed.
- 30 Oct 2021 Results (N=1,135) of pooled analysis from BICSTaR studies presented at the 18th European AIDS Conference
- 08 May 2020 Status changed from recruiting to active, no longer recruiting.